SENSIFAI.HEALTH

More than 1 billion people own a wearable device[1]

Wearables are a commodity, but have not yet moved the needle on health

[1] Wearable Technology Statistics 2025 By Tech and Human

FROM IMMUNE SIGNALS TO PREEMPTIVE CARE

Sensifai Health's proprietary algorithms generate insights from wearables that alert inflammatory events before symptoms, enabling preemptive intervention.

THE PROBLEM

Problem: Delayed Treatment



CURRENT PRACTICE

USE CASE: The average time from symptom onset to treatment for common viral infections is 5 to 7 days

BY THIS TIME:

1. **Treatment is no longer effective**
2. **The infection has been transmitted to others**

THE SOLUTION

Paradigm Shift: Preemptive Treatment



Sensifai Health Proprietary

SENSIFAI

Shift treatment back in time by several days

Prevent severe downstream complications

Rendering invisible immune signals visible

contact@sensifai.health

CLINICALLY VALIDATED

90% Sensitivity

in predicting inflammation surges — proven in controlled clinical trials[1]

1. Hadid et al., The Lancet Digital Health, 2025

2 Billion

data points were used to train our algorithm to predict inflammation without needles

HOW IT WORKS

WEAR
Individuals use any off-the-shelf wearable

DETECT
AI analyzes physiological signals for inflammation patterns

PREDICT
AI correlates data with a personalized composite inflammation score

PROTECT
Individual and clinician alerts

ACT
Intervene before symptoms appear

Device-agnostic platform works with any off the shelf wearable

Traction

2022
McGill University Health Centre
POC demonstrated in a clinical study

2023
Altesa BioSciences
Five-year strategic partnership signed
Value of $10M for Sensifai

2024
KAISER PERMANENTE
Willingness to pay

2025
SAMSUNG
LOI towards pilot

THE LANCET Digital Health
Sensifai clinical study results published

IMPERIAL
Imperial College of London
Clinical validation study completed successfully

2026
3 commercial pilots

contact@sensifai.health

MARKET OPPORTUNITY

Multi-tiered, Scalable Platform

TAM

$45B

General Wellness

Licensing our core AI via API to wearable manufacturers that seek validated clinical insights on their mobile health ecosystem (Samsung, Apple, Huawei etc.)

$61B

Pharma

- Payment for our research SaaS platform during R&D phase of new drugs
- Post marketing- companion app

$195B

Providers & Payers

Preemptive health SaaS platform used by providers and payers aiming to cut costs and streamline processes

VALUE PROPOSITION

FOR PATIENTS

- Continuous at-home monitoring and intervention (initiate your action plan)
- Prevention of hospitalizations
- Improved health outcomes through personalized data insights

FOR PROVIDERS

- Automatic actionable insights
- Prevent adverse events before they occur
- Passive reimbursement (RTM CPT codes available)

FOR PAYERS

- 7x ROI in high risk population such as people living with chronic lung disease
- Reduced hospitalizations and complications

FOR PHARMA

- Improved therapeutic efficacy through optimal timing
- Increased prescriptions with better outcomes
- Right medication, right person, right time

USE CASE & ECONOMICS

People living with chronic lung disease

17B

Respiratory infections annually

$19K

Cost per episode

Exacerbation costs for high-risk patients

90%

Could be prevented with early detection

contact@sensifai.health

Competitive Landscape



*60% (Phillips) vs 90% (Sensifai)

Milestones

Jan 2021
Team founded at McGill University

Dec 2022
1st in the world to detect acute systemic inflammation non-invasively

Sept 2023
IP protected March 2023 Spin-off & license agreement

Nov 2023
Strategic partnership with US based pharma company

Jan 2024
Clinical validation studies launched (UK & US, patients with COPD)

July 2025
Clinical validation – peer reviewed – Lancet Digital Health

Aug 2025
Pre-seed round

Oct 2025
MVP launch – EarlyCue™

contact@sensifai.health

FOUNDING TEAM

Amir Hadid, PhD

Co-founder, CEO

Serial HealthTech entrepreneur with 20+ years building companies at the intersection of human performance monitoring and medical devices. Led LifeBond to acquisition by Becton Dickinson (NYSE: BDX). Scientific Officer (Res.) at IDF Medical Corps, pioneering physiological monitoring under extreme conditions. Now applying this deep research expertise to revolutionize immune health with Sensifai.

Emily McDonald, MD

Co-founder, CMO

Two-time founder and physician-scientist. Co-founded and led MedSafer from inception to commercialization. Associate Professor of Medicine at McGill University Health Centre. Recipient of McGill's Maude Abbott Prize. Trained at Harvard T.H. Chan School of Public Health. Now scaling preventive care with Sensifai Health.

Dennis Jensen, PhD

Co-founder, CSO

Associate Professor and Canada Research Chair in Clinical Exercise and Respiratory Physiology at McGill University. 15+ years of clinical research experience in COPD and a knowledge leader on the potential benefits of wearable biosensors in the era of chronic illness.

Join our Bioconvergence Revolution

contact@sensifai.health